Product Description
Our goal is to destroy the driver of the cancer, usually a bad protein that is produced from bad DNA inside a previously normal cell, transforming it into a cancer cell. Drivers of cancer, such as the deregulated PRDM genes and proteins, were previously thought to be “undruggable” because of the high risk of damaging normal cells. ARIZ set out to prove that by using new genetic information, nanotechnology based drug delivery systems and Nobel prize winning gene and protein altering methodologies, cancer cells could be individually targeted and destroyed, without harming normal cells. ARIZ’s proof of principle studies confirmed that this approach selectively killed multiple types of cancer cells (breast, colon, lung, myeloma, etc.). (Sourced from: https://arizbio.com/mission/)
Mechanisms of Action: PRDM1 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ariz Precision Medicine
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|